JP2014510156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510156A5 JP2014510156A5 JP2014504039A JP2014504039A JP2014510156A5 JP 2014510156 A5 JP2014510156 A5 JP 2014510156A5 JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014504039 A JP2014504039 A JP 2014504039A JP 2014510156 A5 JP2014510156 A5 JP 2014510156A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- topical
- semi
- prostaglandin
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 230000000699 topical effect Effects 0.000 claims 12
- 239000008247 solid mixture Substances 0.000 claims 11
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 8
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 150000004676 glycans Chemical class 0.000 claims 6
- 229920001282 polysaccharide Polymers 0.000 claims 6
- 239000005017 polysaccharide Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000003782 Raynaud disease Diseases 0.000 claims 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 4
- -1 prostaglandin E 1 compound Chemical class 0.000 claims 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 4
- 239000002562 thickening agent Substances 0.000 claims 3
- KIPQYJOLEGBNHQ-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)CN(C)C KIPQYJOLEGBNHQ-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical group CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 claims 2
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical compound CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- PUIBPGHAXSCVRF-QHFGJBOXSA-N prostaglandin C1 Chemical compound CCCCC[C@H](O)\C=C\C1=CCC(=O)[C@@H]1CCCCCCC(O)=O PUIBPGHAXSCVRF-QHFGJBOXSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472988P | 2011-04-07 | 2011-04-07 | |
| US61/472,988 | 2011-04-07 | ||
| PCT/US2012/032577 WO2012139033A1 (en) | 2011-04-07 | 2012-04-06 | Methods and compositions for treating raynaud's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510156A JP2014510156A (ja) | 2014-04-24 |
| JP2014510156A5 true JP2014510156A5 (enExample) | 2015-04-23 |
Family
ID=46969575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504039A Pending JP2014510156A (ja) | 2011-04-07 | 2012-04-06 | レイノー病を治療する方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8940794B2 (enExample) |
| EP (1) | EP2693877A4 (enExample) |
| JP (1) | JP2014510156A (enExample) |
| BR (1) | BR112013025744A2 (enExample) |
| CA (1) | CA2838109C (enExample) |
| MX (1) | MX342511B (enExample) |
| RU (1) | RU2633236C2 (enExample) |
| WO (1) | WO2012139033A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009918A1 (en) | 2003-04-02 | 2005-01-13 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods for the treatment of vasospasm |
| CA2838109C (en) | 2011-04-07 | 2020-06-09 | Nexmed Holdings, Inc. | Topical semisolid prostaglandin e1 composition for treating raynaud's disease |
| CN105120846B (zh) | 2013-02-05 | 2019-10-18 | 普渡制药公司 | 抗篡改的药物制剂 |
| CN109288848A (zh) * | 2018-11-27 | 2019-02-01 | 西安力邦肇新生物科技有限公司 | 前列腺素e1甲酯在制备扩张血管药物中的应用 |
| US20240299413A1 (en) | 2020-08-07 | 2024-09-12 | Eicos Sciences, Inc. | Method of treating systemic sclerosis with symptomatic raynaud's phenomenon by intravenous or subcutaneous iloprost administration |
| CN121772928A (zh) | 2023-07-18 | 2026-03-31 | Btg国际股份有限公司 | 使用伊洛前列素用于治疗冻伤的方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029814A (en) | 1975-12-29 | 1977-06-14 | The Upjohn Company | Phenyl-substituted prostaglandin-e type analogs |
| US4212987A (en) | 1976-09-17 | 1980-07-15 | The Upjohn Company | 2,2-Difluoro-PGE1 analogs |
| US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4820732A (en) | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| US4955878A (en) | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
| US5219885A (en) | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| DE3704825A1 (de) | 1987-02-16 | 1988-08-25 | Froelich Juergen | Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung |
| US5082866A (en) | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| ES2093774T3 (es) | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| CA2107669C (en) | 1992-02-07 | 2004-06-01 | Makoto Okumura | Preparation for treating wounds and hemorrhoides |
| AU7977294A (en) | 1993-10-07 | 1995-05-01 | Odontex, Inc. | Absorption enhancers for topical pharmaceutical formulations |
| US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
| US20020165122A1 (en) | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
| US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| TW473834B (en) | 1998-05-01 | 2002-01-21 | Ibm | Method of doping a gate and creating a very shallow source/drain extension and resulting semiconductor |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US7087240B1 (en) | 1998-06-25 | 2006-08-08 | Lavipharm Laboratories Inc. | Device and method for the treatment of erectile dysfunction |
| US6007824A (en) | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| CA2442479C (en) | 1999-05-13 | 2005-12-13 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin e1 delivery |
| US6118020A (en) | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| CA2400804C (en) | 2000-02-04 | 2009-09-01 | Takeda Chemical Industries, Ltd. | Stable emulsion compositions of cycloalkene derivatives |
| US20060148907A1 (en) | 2002-07-24 | 2006-07-06 | Nicholson David M | Topical antinflammatory preparations of y-terpinene |
| BR0315681A (pt) * | 2002-10-30 | 2005-09-06 | Merck Frosst Canada Inc | Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável |
| US6841574B2 (en) | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| US20050009918A1 (en) | 2003-04-02 | 2005-01-13 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods for the treatment of vasospasm |
| EP2781505A1 (en) * | 2006-10-02 | 2014-09-24 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
| EP2011496A1 (en) | 2007-07-03 | 2009-01-07 | Indena S.P.A. | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
| CA2838109C (en) | 2011-04-07 | 2020-06-09 | Nexmed Holdings, Inc. | Topical semisolid prostaglandin e1 composition for treating raynaud's disease |
-
2012
- 2012-04-06 CA CA2838109A patent/CA2838109C/en active Active
- 2012-04-06 BR BR112013025744A patent/BR112013025744A2/pt not_active Application Discontinuation
- 2012-04-06 WO PCT/US2012/032577 patent/WO2012139033A1/en not_active Ceased
- 2012-04-06 MX MX2013011662A patent/MX342511B/es active IP Right Grant
- 2012-04-06 JP JP2014504039A patent/JP2014510156A/ja active Pending
- 2012-04-06 US US14/110,348 patent/US8940794B2/en active Active
- 2012-04-06 RU RU2013141836A patent/RU2633236C2/ru active
- 2012-04-06 EP EP12767469.5A patent/EP2693877A4/en active Pending
-
2015
- 2015-01-07 US US14/591,487 patent/US9517218B2/en active Active
-
2016
- 2016-07-29 US US15/224,098 patent/US9855231B2/en not_active Expired - Fee Related
-
2017
- 2017-12-15 US US15/844,361 patent/US10632086B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2012054831A3 (en) | Ready to use ketorolac formulations | |
| JP2013542247A5 (enExample) | ||
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| JP2015504871A5 (enExample) | ||
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2014515373A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2012529484A5 (ja) | 高血圧症の防止及び治療のための組成物並びに方法 | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ703808A (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
| JP2010510286A5 (enExample) | ||
| JP2013516493A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2015505295A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013541583A5 (enExample) | ||
| HK1202448A1 (en) | Topical formulation for administering a compound | |
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| JP2013534228A5 (enExample) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2013141836A (ru) | Способы и композиции для лечения болезни рейно |